您当前的位置:
首页 >
文章列表页 >
Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition)
Guideline and Consensus | 更新时间:2025-12-31
    • Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition)

    • China Oncology   Vol. 32, Issue 5, Pages: 451-468(2022)
    • DOI:10.19401/j.cnki.1007-3639.2022.05.011    

      CLC: R736.1
    • Received:28 March 2022

      Revised:2022-05-06

      Published:30 May 2022

    移动端阅览

  • Committee of Nuclear Medicine, Chinese society of Clinical Oncology Expert, Committee of Thyroid Cancer, Chinese society of Clinical Oncology Expert, of Thyroid Disease Society, China International Exchange and Promotive Association for Medical and Health Care Committee, et al. Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition)[J]. China Oncology, 2022, 32(5): 451-468. DOI: 10.19401/j.cnki.1007-3639.2022.05.011.

  •  
  •  
icon
试读结束,您可以激活您的VIP账号继续阅读。
去激活 >
icon
试读结束,您可以通过登录账户,到个人中心,购买VIP会员阅读全文。
已是VIP会员?
去登录 >

0

Views

1132

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)
Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)
Current status and future perspectives on consensus and controversies in advanced breast cancer for 2024
Important research progress in clinical practice for early breast cancer in 2024
Global trends of 131I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)

Related Author

Xichun HU
Yongmei YIN
Hongxia WANG
Association Committee of Cancer Pain Fujian Anti-Cancer
Association Committee of Rehabilitation and Palliative Care China Anti-Cancer
Xiaobo WANG
Tao WANG
Xing LI

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association
Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital
Department of Breast Surgery, the First Affiliated Hospital of China Medical University
Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences; State Key Laboratory of Complex Severe and Rare Diseases; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine
Department of Nuclear Medicine, the First Affiliated Hospital of Anhui Medical University
0